How Old Do You Have to Be to Take Ozempic? Age Rules for Teens and Seniors

    How Old Do You Have to Be to Take Ozempic? Age Rules for Teens and Seniors

    Ozempic is approved for adults 18+ with type 2 diabetes, with no upper age limit. Which GLP-1s are approved for kids and teens, and the 2026 pill trial.

    Written by Dr. Sheri Tomas. Updated November 19, 2026.

    You have to be an adult to take Ozempic as the FDA approved it: the label approves it for adults with type 2 diabetes, and it states that safety and efficacy "have not been established in pediatric patients," meaning in children and teenagers under 18. There is no upper age limit in the label, and older adults made up a meaningful share of the people studied. The confusing part is that the same medicine, semaglutide, is approved for teenagers under a different brand: the Wegovy injection is approved for weight reduction in people aged 12 and older with obesity. Two older GLP-1 medicines, Victoza and Bydureon BCise, are approved for children aged 10 and older with type 2 diabetes. A GLP-1 is a type of medicine that copies a gut hormone involved in blood sugar and appetite. This guide sets out what the labels say, which GLP-1 medicines are approved at which ages as of November 2026, what the 2026 pediatric trial of the Ozempic pill showed, and what parents and older adults should ask a doctor.

    How Old Do You Have to Be to Take Ozempic? The Short Answer

    1. 1Approved age: adults (18 and older) with type 2 diabetes, per the FDA label.
    2. 2Under 18: the label says safety and efficacy have not been established in pediatric patients.
    3. 3No upper age limit: 23.6% of people on Ozempic in the label's pooled trials were 65 or older, and 3.2% were 75 or older.
    4. 4Teens with obesity: the Wegovy injection (also semaglutide) is approved from age 12.
    5. 5Children with type 2 diabetes: Victoza (2019) and Bydureon BCise (2021) are approved from age 10.
    6. 6Ozempic pill: approved for adults only; a teen trial reported results in April 2026, but it is not approved for children as of November 2026.

    Does the Ozempic Label Set a Minimum Age?

    Not with a number, but in effect yes. The FDA label describes Ozempic's blood sugar use as "an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus." An adjunct is something used alongside other treatment, and glycemic control means keeping blood sugar in a healthy range. The key word is "adults."

    The label's Pediatric Use section (section 8.4) is one sentence: "Safety and efficacy of OZEMPIC have not been established in pediatric patients." That does not say Ozempic is known to be dangerous for teenagers. It says the studies needed to show that it works and is safe in that age group have not been done to the FDA's standard for this product, so it is not approved for them. For an overview of what the medicine is and how it works, see what is Ozempic.

    Is There an Upper Age Limit for Ozempic?

    No. The label sets no maximum age. Its Geriatric Use section (section 8.5) reports that in the pooled clinical trials, 744 people treated with Ozempic (23.6%) were 65 or older, and 102 (3.2%) were 75 or older. So older adults were included in the studies, though people aged 75 and over were a small group.

    No age cutoff does not mean age is irrelevant. Doctors usually look more closely at older patients because they are more likely to have kidney problems, take several other medicines, or have a smaller appetite to begin with. Ozempic commonly causes nausea, vomiting and reduced appetite, which can matter more for someone who is frail or eats little. These are reasons for closer follow-up, not reasons the label gives to stop at a certain age. Our article is Ozempic safe covers the label's warnings in more detail.

    GLP-1 Medicines and Approved Ages at a Glance

    GLP-1 medicines and youngest approved age in the US (as of November 2026)

    Medicine
    Approved use
    Youngest approved age

    Ozempic injection (semaglutide)

    Type 2 diabetes in adults

    Not established in pediatric patients

    Ozempic pill (oral semaglutide)

    Type 2 diabetes in adults (approved Feb 4, 2026)

    Not approved in pediatrics; Novo planned a filing in the second half of 2026

    Wegovy injection (semaglutide)

    Weight reduction in people with obesity

    12 years (approved December 2022)

    Wegovy tablets and Wegovy 7.2 mg injection

    Weight reduction in adults

    Not established in pediatric patients

    Victoza (liraglutide)

    Type 2 diabetes

    10 years (approved June 2019)

    Bydureon BCise (exenatide extended-release)

    Type 2 diabetes

    10 years, ages 10 to 17 (reported July 2021)

    Foundayo (orforglipron)

    Weight reduction in adults

    Not established; pediatric studies deferred

    Why Is Wegovy Approved for Teens When Ozempic Isn't?

    Ozempic and Wegovy contain the same active ingredient, semaglutide, but they are separate products with separate approvals, doses and trial programs. Approval is granted for a specific use in a specific group of people, based on trials in that group. Novo Nordisk ran a trial of Wegovy in teenagers with obesity; it has not won a pediatric approval for the Ozempic injection.

    The Wegovy label approves the injection for weight reduction in "adults and pediatric patients aged 12 years and older with obesity." Its pediatric section says effectiveness has been established in patients 12 and older and not in those under 12. The pediatric trial, listed in the label as Study 10, enrolled 201 patients aged 12 and older for 68 weeks. According to coverage of Novo Nordisk's December 2022 announcement, average BMI (body mass index, a measure of weight relative to height) fell 16.1% with semaglutide and rose 0.6% with placebo.

    Two limits are worth knowing. First, the Wegovy label says pediatric patients had "greater incidences of cholelithiasis, cholecystitis, hypotension, rash, and urticaria" than adults. In plain terms: gallstones, gallbladder inflammation, low blood pressure, rash and hives. Second, not every Wegovy product is approved for teens. The label states that the safety and effectiveness of Wegovy tablets have not been established in pediatric patients, and that the safety of the 7.2 mg injection has not been established in pediatric patients either. Our Ozempic vs Wegovy comparison and our explainer on Ozempic vs semaglutide go through the brand differences.

    Which GLP-1 Medicines Are Approved for Children With Type 2 Diabetes?

    Two older GLP-1 medicines are approved for children with type 2 diabetes. On June 17, 2019, the FDA approved Victoza (liraglutide) for patients aged 10 and older. The FDA described it as the first non-insulin drug approved to treat type 2 diabetes in pediatric patients since metformin in 2000. In the trial of 134 pediatric patients behind the approval, about 64% of children on Victoza reached an A1C below 7%, compared with 37% on placebo. A1C is a blood test that reflects average blood sugar over roughly three months.

    In July 2021, Bydureon BCise (extended-release exenatide) was reported approved for children aged 10 to 17 with type 2 diabetes. In its 24-week trial of 82 pediatric participants, A1C fell 0.25 percentage points on Bydureon BCise and rose 0.45 points on placebo. For a broader look at the drug class, see our guide to GLP-1 medications.

    What Did Pediatric GLP-1 Trials Show?

    Pediatric GLP-1 trial results reported in the sources (dates as published)

    Medicine and trial
    Who was studied
    Main result

    Wegovy injection, teen trial (reported Dec 2022)

    201 patients aged 12 and older with obesity, 68 weeks

    Average BMI −16.1% vs +0.6% on placebo (per press coverage)

    Victoza (approved June 2019)

    134 pediatric patients with type 2 diabetes

    About 64% reached A1C below 7% vs 37% on placebo

    Bydureon BCise (reported July 2021)

    82 pediatric patients with type 2 diabetes, 24 weeks

    A1C −0.25% vs +0.45% on placebo

    Ozempic pill, PIONEER TEENS (reported Apr 2026)

    132 patients aged 10 to 17 with type 2 diabetes, 52 weeks

    A1C fell 0.83 points more than placebo at week 26

    These trials used different medicines, different groups of children and different measures, so the numbers cannot be compared with each other. They show what each product achieved against placebo in its own trial.

    What About the New Ozempic Pill and Kids?

    On February 4, 2026, the FDA approved oral semaglutide, previously sold in the US as Rybelsus, under the Ozempic name for adults with type 2 diabetes. Like the injection, it is an adult medicine. Our page on Ozempic tablets explains how the pill is taken.

    In April 2026, Novo Nordisk reported results from PIONEER TEENS, a phase 3a trial of oral semaglutide in 132 children and teens aged 10 to 17 with type 2 diabetes, lasting 52 weeks. Participants took the pill on top of metformin, basal (long-acting) insulin, or both. At week 26, A1C fell 0.83 percentage points more with oral semaglutide than with placebo. As of the sources we found, these results had been released by the company and reported in the press, not published as a full peer-reviewed paper.

    Novo Nordisk said it planned to file for a US and EU label expansion in the second half of 2026. We found no source confirming that the filing has been made or giving an FDA decision date. As of November 2026, the Ozempic pill is not approved for anyone under 18.

    Can a Doctor Prescribe Ozempic to a Teenager Off-Label?

    In the US, doctors are generally allowed to prescribe an approved drug for a use or age group not listed on its label. This is called off-label prescribing. It happens across medicine, but it means the FDA has not reviewed evidence for that specific use, and insurers may be less likely to cover it.

    For a teenager, a key question is why Ozempic rather than a product that is approved for their age and condition. A teen with obesity has an approved semaglutide option in the Wegovy injection from age 12, and a child with type 2 diabetes has approved GLP-1 options from age 10. Any decision about using a GLP-1 in a young person belongs with their pediatrician or a pediatric specialist who knows their history. We do not give doses for off-label use. Our guide on how to get prescribed Ozempic covers the usual prescribing process for adults, and is Ozempic approved for weight loss explains why Ozempic and Wegovy have different labeled uses.

    What About Newer GLP-1 Pills Like Foundayo?

    Foundayo (orforglipron), a once-daily GLP-1 pill approved in April 2026 for weight reduction, is also an adult-only medicine. Its FDA approval letter, dated April 1, 2026, defers the required studies in children and adolescents. Deferring means the company must complete them after approval. One of them, ADVANCE-ATTAIN-ADOLESCENTS in ages 12 to under 18, has a final report due in December 2028.

    When to Talk to Your Doctor

    1. 1Your child or teen has been diagnosed with type 2 diabetes or obesity and you want to know which medicines are approved for their age.
    2. 2Someone has suggested Ozempic for a person under 18.
    3. 3You are 65 or older and starting Ozempic, especially if you have kidney disease, take several other medicines, or have a poor appetite.
    4. 4Nausea, vomiting or diarrhea make it hard to eat or drink enough, which can lead to dehydration.
    5. 5Pain in the upper right belly, fever, or yellowing of the skin or eyes, which can be signs of gallbladder problems (a risk seen more often in teens on Wegovy).
    6. 6Severe belly pain that does not go away, with or without vomiting.

    What Should Parents Ask the Pediatrician?

    If you are a parent weighing a GLP-1 medicine for a child, or an older adult starting Ozempic, these questions can make the appointment more useful:

    1. 1Which medicines are FDA-approved for my child's age and condition, and why would you choose one over another?
    2. 2If you are suggesting a medicine off-label, what evidence supports it, and will insurance cover it?
    3. 3What monitoring is needed: blood tests, weight checks, blood pressure, and how often?
    4. 4What gallbladder or other warning signs should we watch for, given what was seen in teen trials?
    5. 5How will nutrition, growth and activity be supported alongside the medicine?
    6. 6For older adults: are my kidney function and other medicines a concern, and how should I handle nausea or a low appetite?
    7. 7What is the plan if the medicine is stopped, and what happens to blood sugar or weight then?

    It helps to bring a list of all current medicines and supplements and a record of recent blood sugar or A1C results. For adults with diabetes, our page on Ozempic for diabetes explains where Ozempic fits in treatment.

    The Bottom Line

    Ozempic is approved for adults with type 2 diabetes, and its label says safety and efficacy have not been established in anyone under 18. There is no upper age limit; about a quarter of people in the label's trials were 65 or older. For younger patients, approved options exist: the Wegovy injection (the same molecule) from age 12 for obesity, and Victoza and Bydureon BCise from age 10 for type 2 diabetes. The Ozempic pill showed lower A1C in a 2026 teen trial, but it is not approved for children as of November 2026. Any GLP-1 decision for a young person or a frail older adult should be made with a doctor who knows their full history.

    FAQ

    Ozempic is not FDA-approved for anyone under 18; the label says safety and efficacy have not been established in pediatric patients. A 16-year-old with obesity has an approved semaglutide option in the Wegovy injection (from age 12), and a teen with type 2 diabetes has approved options such as Victoza and Bydureon BCise (from age 10). A pediatrician should guide the choice.

    No. As of November 2026, neither the Ozempic injection nor the Ozempic pill is approved for teenagers. Novo Nordisk reported a teen trial of the pill in April 2026 and said it planned to file for approval in the second half of 2026.

    No. The label sets no upper age limit. In its pooled trials, 23.6% of people on Ozempic were 65 or older and 3.2% were 75 or older. Older adults may need closer follow-up for kidney function, other medicines and appetite.

    The Wegovy injection is approved for weight reduction in adults and in children aged 12 and older with obesity. Wegovy tablets and the 7.2 mg injection are not established in pediatric patients.

    No. The Ozempic pill was approved on February 4, 2026 for adults with type 2 diabetes. The PIONEER TEENS trial in ages 10 to 17 reported lower A1C than placebo, but the pill was not approved for children as of November 2026.

    Victoza (liraglutide) has been approved since 2019 for patients aged 10 and older, and Bydureon BCise (exenatide extended-release) since 2021 for ages 10 to 17.

    Sources

    This article is general information based on FDA labels, FDA documents and news reports, and it is not a substitute for advice from a doctor. Ozempic, Wegovy and Victoza are made by Novo Nordisk; PIONEER TEENS results come from company announcements reported in the press.

    Dr. Sheri Tomas

    Author

    Published November 19, 2026
    Share:TwitterFacebook

    Comments (0)

    Be the first to comment on this article.

    More articles

    How Does Ozempic Work?